These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34125445)

  • 41. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
    Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
    J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
    Yin SJ; Wang WJ; Zhang JY
    Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
    Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
    Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer.
    Ingebrigtsen VA; Boye K; Tekle C; Nesland JM; Flatmark K; Fodstad O
    Int J Cancer; 2012 Dec; 131(11):2528-36. PubMed ID: 22473715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
    Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
    Chavin G; Sheinin Y; Crispen PL; Boorjian SA; Roth TJ; Rangel L; Blute ML; Sebo TJ; Tindall DJ; Kwon ED; Karnes RJ
    Clin Cancer Res; 2009 Mar; 15(6):2174-80. PubMed ID: 19276267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.
    Aung PP; Parra ER; Barua S; Sui D; Ning J; Mino B; Ledesma DA; Curry JL; Nagarajan P; Torres-Cabala CA; Efstathiou E; Hoang AG; Wong MK; Wargo JA; Lazar AJ; Rao A; Prieto VG; Wistuba I; Tetzlaff MT
    Clin Cancer Res; 2019 Jun; 25(11):3455-3467. PubMed ID: 30808776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
    Kim GE; Kim NI; Park MH; Lee JS
    Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
    Shao L; He Q; Wang J; He F; Lin S; Wu L; Gao Y; Ma W; Dong J; Yang X; Li F
    Cell Death Discov; 2021 Jun; 7(1):145. PubMed ID: 34131111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
    Husain I; Shukla S; Soni P; Husain N
    J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
    Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
    Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
    Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
    Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.
    Lin L; Cao L; Liu Y; Wang K; Zhang X; Qin X; Zhao D; Hao J; Chang Y; Huang X; Liu B; Zhang J; Lu J; Ge Q
    Leukemia; 2019 Jun; 33(6):1475-1486. PubMed ID: 30573782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
    Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
    Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.